Objective To summarize the clinical characteristics of foreign accent syndrome (FAS) among Chinese. Methods The journal articles published in Chinese between 1980 and 2011 were retrieved with three Chinese translated versions of FAS as the key words, and 38 articles in line with the inclusion criteria were systematically analyzed. Results and Conclusion Each year, about (3.06±1.65) cases were published on FAS ever since 1996. The age of FAS patients was averagely around 38.10 years, and of the reported cases, there were 26 males and 23 females, there is no significant difference in gender (χ2=0.184, P=0.668). The etiological factors of FAS were identified mainly as injury (59.19%), stroke (32.65%) and psychogenic disorder (8.16%), and 65.31% of the focus were found at the left side of brain.85.72 % of the FAS patients were seen to be speaking a new dialect used by a larger population. 80% of the patients who didn't suffer from a coma changed their accent in 72 h following the injury, while 72.73% of those once in a coma changed their accent as they gained consciousness.The prognosis of FAS was fine, with an improvement rate of 70.83%, and 73.53 % of the patients began to recover less than 3 months later following the injury.

Objective To investigate the preventive and therapeutic effects of lamivudine and entecavir on hepatitis B virus (HBV)reacti-vation among non-Hodgkin lymphoma (NHL)patients with chronic HBV infection during chemotherapy.Methods From January 2008 to April 2013,a total of 94 NHL patients with HBV infection were recruited from our hospital and divided into lamivudine treatment group and entecavir treatment group.The lamivudine treatment group received chemotherapy with lamivudine (100 mg/d),and the entecavir treatment group received chemotherapy with entecavir (0.5 mg/d).The rates of virological breakthrough,primary non -response,and virological breakthrough-related hepatitis flare were compared between groups.The t-test was used for comparison between two groups of independent samples;one-way analysis of variance was conducted for comparison between three groups of independent samples;the chi -square test was used to conduct intergroup comparison.Results For the patients with HBV DNA levels lower than 103 copies/ml before anti -HBV treatment,no significant difference was found in the rate of virological breakthrough or rate of hepatitis flare between lamivudine treatment group and entecavir treatment group (χ2 =1.03,P>0.05).For the patients with HBV DNA levels higher than 103 copies/ml before anti-HBV treatment,the lamivudine treatment group had a virological breakthrough rate of 37.5%,a primary non-response rate of 9.4%,a hepatitis flare rate of 28.1%,and a liver failure rate of 3.1%,and the aforementioned rates for entecavir treatment group were 3.1%,0, 0,and 0,respectively;there were significant differences in the rates of virological breakthrough and hepatitis flare between the two groups (χ2 =11.68,P<0.05;χ2 =10.47,P<0.05).Conclusion Among NHL patients with HBV infection whose HBV DNA levels are lower than 103 copies/ml,the preventive and therapeutic effects of lamivudine and entecavir on HBV reactivation are similar;among NHL patients with HBV infection whose HBV DNA levels are higher than 103 copies/ml,those treated with entecavir have lower rates of virological break-through and hepatitis flare than those treated with lamivudine,which helps patients have a smoother progress of chemotherapy.